Dose Optimization Study of Idelalisib in Follicular Lymphoma
This study will optimize the safety and efficacy of chronic administration of idelalisib in
participants with follicular lymphoma (FL) and evaluate the overall safety profile of
idelalisib and the overall response rate (ORR) by Week 24.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society